Pneumopathie à éosinophiles chez un patient atteint de psoriasis en plaques traité par ustékinumab

Bretèque, M. Amy de la; Vecchi, Corinne Appere de; Zéboulon, C.; Zaïen, I.; Sigal, M.-L.; Mahé, E.

doi:10.1016/j.annder.2014.11.004

Cited by 7 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified 12 postmarketing cases, including 8 from the FAERS database and 4 cases from PubMed. [6][7][8][9] The 12 cases comprised 7 interstitial pneumonia (58%), 3 eosinophilic pneumonia (25%), 1 organizing pneumonia (8%), and 1 hypersensitivity pneumonitis (8%) diagnoses. Of the 12 cases, 7 (58%) were men and 5 (42%) were women, with a median (range) age of 63 (27-80) years.…”

Section: Resultsmentioning

confidence: 99%

Association of Noninfectious Pneumonia With Ustekinumab Use

2019

View full text Add to dashboard Cite

and Drug Administration (FDA) conducts ongoing public health safety surveillance for drug and therapeutic biologic products. Identifying cases of acute and subacute noninfectious pneumonia supports the public health mission of the FDA.OBJECTIVE To identify and analyze postmarketing cases of noninfectious pneumonia associated with ustekinumab use. DESIGN, SETTING, AND PARTICIPANTSThis retrospective analysis of postmarketing (spontaneous) case reports reviewed the FDA Adverse Event Reporting System (FAERS) and the PubMed databases from September 25, 2009, through November 20, 2017. Twelve cases of new-onset acute and subacute noninfectious pneumonia were identified after general marketing of ustekinumab. Cases were excluded if the time to symptom onset was more than 2 years from ustekinumab initiation and if an alternative origin for the noninfectious pneumonia (other than drug-induced) was reported. MAIN OUTCOMES AND MEASURESCases of noninfectious pneumonia associated with ustekinumab use were analyzed for baseline and demographic information, reason for ustekinumab use, symptoms, time to onset, dose sequence, laboratory and diagnostic information, and clinical outcome. RESULTSOf the 12 cases, 8 were identified from the FAERS database and 4 from PubMed. The 12 cases (7 men [58%] and 5 women [42%], with a median [range] age of 63 [27-80] years) included 7 interstitial pneumonia (58%), 3 eosinophilic pneumonia (25%), 1 organizing pneumonia (8%), and 1 hypersensitivity pneumonitis (8%) diagnoses. All 12 cases reported a serious outcome, including 7 hospitalizations (58%) and 1 respiratory failure requiring mechanical ventilation (8%). No outcome of death was reported. All 12 cases were supportive of a temporal association; specifically, in 9 cases (75%), the pulmonary symptoms appeared after 1 to 3 doses of ustekinumab. In addition, 7 cases (58%) of positive dechallenge were reported, including 1 case of a positive rechallenge. CONCLUSIONS AND RELEVANCEThe postmarketing cases suggest an association between noninfectious pneumonia and use of ustekinumab; these findings have led to the addition of a new warning for ustekinumab users regarding the risk of developing noninfectious pneumonia.

show abstract

Section: Resultsmentioning

confidence: 99%

Association of Noninfectious Pneumonia With Ustekinumab Use

2019

View full text Add to dashboard Cite

show abstract

“…A drug-induced interstitial lung disease (DILD) secondary to ustekinumab was diagnosed. In 2015, the case of a 71-year-old patient with psoriasis treated with ustekinumab who developed eosinophilic pneumonia was reported [147]. In 2017, Ali et al described the case of a 61-year-old patient treated with ustekinumab for worsening psoriasis who developed ustekinumab-induced hypersensitivity pneumonitis 5 weeks after starting therapy [148].…”

Section: Ustekinumabmentioning

confidence: 99%

Lung Involvement in Inflammatory Bowel Diseases: Shared Pathways and Unwanted Connections

Cavalli,

Gabbiadini,

Dal Buono

et al. 2023

JCM

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) are chronic, relapsing inflammatory disorders of the gastrointestinal tract, frequently associated with extraintestinal manifestations (EIMs) that can severely affect IBD patients’ quality of life, sometimes even becoming life-threatening. Respiratory diseases have always been considered a rare and subsequently neglected extraintestinal manifestations of IBD. However, increasing evidence has demonstrated that respiratory involvement is frequent in IBD patients, even in the absence of respiratory symptoms. Airway inflammation is the most common milieu of IBD-related involvement, with bronchiectasis being the most common manifestation. Furthermore, significant differences in prevalence and types of involvement are present between Crohn’s disease and ulcerative colitis. The same embryological origin of respiratory and gastrointestinal tissue, in addition to exposure to common antigens and cytokine networks, may all play a potential role in the respiratory involvement. Furthermore, other causes such as drug-related toxicity and infections must always be considered. This article aims at reviewing the current evidence on the association between IBD and respiratory diseases. The purpose is to raise awareness of respiratory manifestation among IBD specialists and emphasize the need for identifying respiratory diseases in early stages to promptly treat these conditions, avoid worsening morbidity, and prevent lung damage.

show abstract